Chinese drugmaker Haixi Pharma shares surged 103% in Hong Kong grey market.
Haixi Pharmaceuticals was established in Fuzhou in March 2012. Haixi Pharma is a pharmaceutical enterprise built around the Marketing Authorization Holder (MAH) system, covering the entire industry value chain from R&D, clinical research, and manufacturing to commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.